APLT - Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia
2024-05-29 03:19:57 ET
Summary
- Applied Therapeutics is a clinical-stage biotech focused on treating symptoms of galactosemia in the central nervous system.
- Govorestat (AT-007) is in late-stage regulatory approval for galactosemia, with a PDUFA date set for November 2024.
- APLT holds $146.5 million in cash, ensuring a sufficient runway to FDA approval and initial product revenues by early 2025.
- The Company has a diversified pipeline, including AT-007 for SORD Deficiency and PMM2-CDG and AT-001 for diabetic cardiomyopathy and peripheral neuropathy.
- I think APLT's valuation seems reasonable given its progress and financials, so I rate it a "strong-buy" despite biotech risks.
...
Applied Therapeutics: A Strong Buy With AT-007 Nearing Approval For Galactosemia